Analysis of MTOR Inhibition-involved Pathway in Ovarian Clear Cell Adenocarcinoma

Overview

Journal Acta Histochem Cytochem

Specialty Biochemistry

Date 2011 May 27

PMID 21614172

Citations 7

Authors

Makiko Harasawa

Masanori Yasuda

Takeshi Hirasawa

Masaki Miyazawa

Masako Shida

Toshinari Muramatsu

Kensho Douguchi

Naruaki Matsui

Susumu Takekoshi

Hiroshi Kajiwara

R Yoshiyuki Osamura

Mikio Mikami

Affiliations

Soon will be listed here.

Abstract

This study was designed to clarify the mechanism of the mammalian target of rapamycin (mTOR)-hypoxia inducible factor-1 (HIF-1) pathway using the cultured cell strain derived from human ovarian clear cell adenocarcinoma (CCA). Everolimus (a derivative of rapamycin)-treated cells and non-treated cells did not show any difference in mTOR expression. But, phosphorylated-mTOR (p-mTOR) expression significantly decreased in the treated cells, and mTOR-related factors such as phosphorylated-4E-BP1 (p-4E-BP1), HIF-1α, and vascular endothelial growth factor (VEGF) in the downstream region of mTOR revealed a marked decrease in expression. The analysis of influences of the drug on the HIF-1α degradation system showed an increase in von-Hippel Lindau (VHL) expression in the treated cells. Increase of cleaved caspase-3, one of key factors involved in apoptosis, was also shown in the treated cells. In the next step, using nude mice implanted with RMG-1 cells, a decrease in tumor size was demonstrated in 4 of the 7 mice which were orally administered with everolimus. As a result, it was suggested that everolimus administration would be helpful as an anti-tumor therapy for CCA not only via down-regulation of p-mTOR but also degradation of HIF-1α by VHL and induction of apoptosis by cleaved caspase-3.

Citing Articles

Dual Roles of the AMP-Activated Protein Kinase Pathway in Angiogenesis.

Li Y, Sun R, Zou J, Ying Y, Luo Z Cells. 2019; 8(7).

PMID: 31331111 PMC: 6678403. DOI: 10.3390/cells8070752.

Inhibition of Mammalian Target of Rapamycin Signaling with Rapamycin Prevents Trauma-Induced Heterotopic Ossification.

Qureshi A, Dey D, Sanders E, Seavey J, Tomasino A, Moss K Am J Pathol. 2017; 187(11):2536-2545.

PMID: 29029772 PMC: 5809339. DOI: 10.1016/j.ajpath.2017.07.010.

Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report.

Takatori E, Shoji T, Miura Y, Takada A, Takeuchi S, Sugiyama T Onco Targets Ther. 2014; 7:165-9.

PMID: 24511239 PMC: 3913549. DOI: 10.2147/OTT.S54745.

Induction of β-Defensin Expression by Porphyromonas gingivalis-Infected Human Gingival Graft Transplanted in nu/nu Mouse Subdermis.

To M, Kamata Y, Saruta J, Shimizu T, Sato T, Kondo Y Acta Histochem Cytochem. 2013; 46(1):25-34.

PMID: 23554537 PMC: 3596604. DOI: 10.1267/ahc.12033.

Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Hiss D J Oncol. 2012; 2012:737981.

PMID: 22481932 PMC: 3306947. DOI: 10.1155/2012/737981.

References

Costa L, Balcells M, Edelman E, Nadler L, Cardoso A . Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. Blood. 2005; 107(1):285-92. PMC: 1895363. DOI: 10.1182/blood-2005-06-2208. View

Albert J, Kim K, Cao C, Lu B . Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther. 2006; 5(5):1183-9. DOI: 10.1158/1535-7163.MCT-05-0400. View

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J . Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27(16):2630-7. DOI: 10.1200/JCO.2008.18.8391. View

Jiang H, Feng Y . Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. Int J Gynecol Cancer. 2006; 16 Suppl 1:405-12. DOI: 10.1111/j.1525-1438.2006.00310.x. View

Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M . Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002; 8(2):128-35. DOI: 10.1038/nm0202-128. View

Chiu M, Katz H, BERLIN V . RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A. 1994; 91(26):12574-8. PMC: 45481. DOI: 10.1073/pnas.91.26.12574. View

SCHULER W, Sedrani R, Cottens S, Haberlin B, Schulz M, Schuurman H . SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997; 64(1):36-42. DOI: 10.1097/00007890-199707150-00008. View

Yuan R, Kay A, Berg W, Lebwohl D . Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009; 2:45. PMC: 2775749. DOI: 10.1186/1756-8722-2-45. View

Peng D, Wang J, Zhou J, Wu G . Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun. 2010; 394(3):600-5. PMC: 4063277. DOI: 10.1016/j.bbrc.2010.03.029. View

10.

Gnarra J, Tory K, Weng Y, Schmidt L, Wei M, Li H . Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994; 7(1):85-90. DOI: 10.1038/ng0594-85. View

11.

Rathmell W, Chen S . VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther. 2007; 8(1):63-73. PMC: 2873028. DOI: 10.1586/14737140.8.1.63. View

12.

Wang Z, Zhou J, Fan J, Qiu S, Yu Y, Huang X . Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res. 2008; 14(16):5124-30. DOI: 10.1158/1078-0432.CCR-07-4774. View

13.

Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S . Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int. 2009; 59(1):19-27. DOI: 10.1111/j.1440-1827.2008.02320.x. View

14.

Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, OReilly T . The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005; 120(6):747-59. DOI: 10.1016/j.cell.2004.12.040. View

15.

Choi J, Chen J, Schreiber S, Clardy J . Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 1996; 273(5272):239-42. DOI: 10.1126/science.273.5272.239. View

16.

Tokunaga C, Yoshino K, Yonezawa K . mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun. 2003; 313(2):443-6. DOI: 10.1016/j.bbrc.2003.07.019. View

17.

Miyajima K, Takekoshi S, Itoh J, Kakimoto K, Miyakoshi T, Osamura R . Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors. Acta Histochem Cytochem. 2010; 43(2):33-44. PMC: 2875861. DOI: 10.1267/ahc.09034. View

18.

Chen J, Zheng X, Brown E, Schreiber S . Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci U S A. 1995; 92(11):4947-51. PMC: 41824. DOI: 10.1073/pnas.92.11.4947. View

19.

Pavlovich C, Schmidt L, Phillips J . The genetic basis of renal cell carcinoma. Urol Clin North Am. 2003; 30(3):437-54, vii. DOI: 10.1016/s0094-0143(03)00023-5. View

20.

Fujita M, Yasuda M, Kitatani K, Miyazawa M, Hirabayashi K, Takekoshi S . An up-to-date anti-cancer treatment strategy focusing on HIF-1alpha suppression: its application for refractory ovarian cancer. Acta Histochem Cytochem. 2008; 40(5):139-42. PMC: 2156042. DOI: 10.1267/ahc.07024. View